A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity
•We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Muc...
Saved in:
Published in | Oral oncology Vol. 136; p. 106190 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Mucoepidermoid carcinoma of the parotid gland, anti-PD-1 immunotherapy could be considered to further improve therapeutic qualities and prognosis.•Our case showed an encouraging efficacy of Capecitabine plus sintilimab combination therapy. This promising avenue deserves further study to apply this combination regimen to clinical practice. |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 |
ISSN: | 1368-8375 1879-0593 |
DOI: | 10.1016/j.oraloncology.2022.106190 |